Pharmaceuticals

With $82M in funding and novel gene insertion technology, Averna Therapeutics is poised to make waves at the pivotal J.P. Morgan Healthcare Conference.

A new study reveals the hidden quality-of-life toll of a common virus on transplant patients, highlighting the urgent need for targeted new therapies.

Biocytogen and Acepodia are expanding their partnership to create next-gen ADCs with two targets and two warheads, aiming to defeat drug-resistant cancers.

An expanded partnership aims to create next-gen cancer therapies by combining bispecific antibodies with two distinct drugs to overcome tumor resistance.

The biotech firm lands a major private placement, extending its cash runway to 2028 and signaling strong investor confidence in its novel drug platform.

Ocugen heads to a top investor conference with a bold plan for its gene-agnostic therapy, aiming to treat blindness and secure its future in a crowded market.

With blockbuster preliminary sales and rapid patient adoption, Liquidia's new inhaled therapy is challenging established players in the lung disease space.

Kezar Life Sciences faces a critical FDA meeting for its novel liver disease drug, a decision that could bring hope to patients and define the company's future.

A major pharma giant is betting on artificial intelligence to accelerate cancer drug discovery, a move that could reshape the future of oncology treatment.

Belgian biotech MRM Health gets the green light for a Phase 2b trial of MH002, a novel 'living drug' aimed at revolutionizing ulcerative colitis care.

A legal battle over the blockbuster cancer drug Jemperli escalates, with billions in future royalties and a company's strategic future on the line.

Savara's potential new therapy for autoimmune PAP, MOLBREEVI, gets a powerful partner in PANTHERx Rare, promising a new era of comprehensive patient care.

Alessa Therapeutics’ rice-sized implant, Enolen, earns FDA Fast Track, promising a new era for prostate cancer therapy without debilitating side effects.

As healthcare costs surge, WTW names Sheila Nordquist its new North America H&B leader. Her mandate: drive growth and navigate an evolving benefits landscape.

Paris-based Enodia Therapeutics lands €20.7M to advance its AI platform that degrades disease-causing proteins at the point of synthesis, targeting new cures.

New research reveals a stark disconnect between clinical views and patient reality in atopic dermatitis, with millions suffering severe, overlooked impacts.

Global consulting giant Andersen partners with niche firm Scimitar to tackle pharma's biggest challenges, signaling a new model for expertise at scale.

A new class of painkillers promises the power of opioids with a far lower risk of addiction. Tris Pharma's cebranopadol could reshape pain management.

NeuroSense adds world-renowned expert Prof. Steven Arnold to its board, a major vote of confidence in its multi-target Alzheimer's drug, PrimeC.

A new study on oral testosterone therapy for men 65-80 could reshape geriatric care, challenge FDA guidelines, and unlock a multi-billion dollar market.